Company intelligence / Profile preview

JADO Technologies GmbH

Dresden, Sachsen, Germanylife-sciences-europe.com ↗

Ownership: Private
Employees: ~11
Development stage: Other

Overview

JADO Technologies completed Phase IIa clinical trials for its lead RAFT modulator in atopic dermatitis with positive results. The company also initiated Phase II trials for urticaria. Their lead compound TF002 was being evaluated in cutaneous mastocytosis.

Therapeutic areas: PulmonologyDermatologyImmunology
Modalities: Small molecules
Industry: Biotech

Partnerships

University of BonnAeterna Zentaris

Beyond the preview

Go deeper on JADO Technologies GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JADO Technologies GmbH.

Explore the full profile